Ascend Gene & Cell Therapies
Wes McConnell currently serves as Chief Financial Officer at Ascend Advanced Therapies since July 2022, focusing on the development of high-quality gene therapies. Prior to this role, Wes held the position of Director of Finance at Bavarian Nordic, A/S from December 2010 to July 2022, and briefly served as Director of Government Programs at AstraZeneca during the H1N1 pandemic. Additional experience includes Director of Government Reporting at Bavarian Nordic A/S, Supervisor of International Finance at Hughes Network Systems, and Contracts Administrator at Casals & Associates, Inc. Wes's academic credentials include an MBA in International Business from The George Washington University, a Post Masters Certificate in Accounting, and a Certificate in Essentials of Leadership from London Business School, among other qualifications.
This person is not in any offices
Ascend Gene & Cell Therapies
Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.